Summary
Background Wait list sizes for specialist secondary care have soared in recent years. Dermatology is a good candidate service for retaining patients in primary care and avoiding unnecessary waits to see a specialist. A dermatology dialogue service between primary and secondary care (DDPS) was developed in Norfolk and Waveney, eastern England. The service involved primary care referrers uploading patient images of skin complaints for review by and dialogue with secondary specialists to see if the patient could be retained in primary care, or should be referred to secondary care routinely, urgently or on the two week wait cancer pathway.
Objectives To evaluate service performance with respect to specific targets including reduction in secondary care wait list growth in the period March 2021-March 2022 inclusive.
Methods Service activity was summarized with respect to speed of resolution, case counts and dispositions. Clinician and patient satisfaction were canvased with structured questionnaires. Actual new referral counts were compared to projections based on historical data. Wait list growth was compared to other specialisms and other areas. Wait times to receive first treatment at start and end of monitoring period were monitored.
Results Over 3600 patients were enrolled in the DDPS system. Over 98% of cases were reported by the dermatologists within 36 hours. Clinician and patient satisfaction were high. Frequently asked questions and conditions were highlighted by dermatologists to design and deliver an educational event for primary care clinicians that was well received. Wait list growth to see dermatology in the commissioning area was smaller for dermatology than other large specialisms, and mostly smaller growth than dermatology wait lists commissioned by other NHS commissioners. Negative impact on the urgent priority (cancer pathway) wait list could not be observed.
Conclusions The DDPS was satisfactory to clinicians and patients and coincided with smaller dermatology wait list growth than might otherwise have been expected.
Competing Interest Statement
BW is both an NHS consultant dermatologist and a reporting consultant dermatologist with Xyla Elective Care which is an outsourcing company that was contracted to provide clinical support and collect patient/clinician satisfaction with the DDPS service. No other authors has interests to declare.
Funding Statement
This evaluation was funded by the UEA Health and Social Care Partnership (UEAH&SCP). UEAH&SCP were not involved in the data collection, analysis and manuscript preparation. Dr. Brainard is affiliated to the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emergency Preparedness and Response at Kings College London in partnership with the UK Health Security Agency (UK HSA) and collaboration with the University of East Anglia. The views expressed are those of the author(s) and not necessarily those of the UEAH&SCP, NHS, NIHR, UEA, UK Department of Health, UKHSA, any funder, private company or NHS organisations involved with service delivery.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Consent to undertake this service evaluation was granted by North Norfolk Primary Care (26 March 2021) and by the UEA Faculty of Medicine and Health Sciences Research Ethics Subcommittee on 26 Nov 2021 (their Ref. ETH21-22-0034).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding This evaluation was funded by the UEA Health and Social Care Partnership (UEAH&SCP). UEAH&SCP were not involved in the data collection, analysis and manuscript preparation. Dr. Brainard is affiliated to the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emergency Preparedness and Response at King’s College London in partnership with the UK Health Security Agency (UK HSA) and collaboration with the University of East Anglia. The views expressed are those of the author(s) and not necessarily those of the UEAH&SCP, NHS, NIHR, UEA, UK Department of Health, UKHSA, any funder, private company or NHS organisations involved with service delivery.
Institutional Review and Ethics Approval Consent to undertake this service evaluation was granted by North Norfolk Primary Care (26 March 2021) and by the UEA Faculty of Medicine and Health Sciences Research Ethics Subcommittee on 26 Nov 2021 (their Ref. ETH21-22-0034).
Declarations of interest BW is both an NHS consultant dermatologist and a reporting consultant dermatologist with Xyla Elective Care which is an outsourcing company that was contracted to provide clinical support and collect patient/clinician satisfaction with the DDPS service.
Data Availability
All data are patient sensitive and not available.
